Compare KGS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | RYTM |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2023 | 2017 |
| Metric | KGS | RYTM |
|---|---|---|
| Price | $59.08 | $102.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $57.17 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.6M | 646.7K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | 28.34 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | N/A |
| Revenue This Year | $12.30 | $55.34 |
| Revenue Next Year | $7.96 | $86.06 |
| P/E Ratio | $326.40 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $30.06 | $74.50 |
| 52 Week High | $77.68 | $122.20 |
| Indicator | KGS | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 46.08 |
| Support Level | $55.10 | $98.30 |
| Resistance Level | $59.29 | $113.51 |
| Average True Range (ATR) | 2.95 | 3.76 |
| MACD | -0.69 | -1.65 |
| Stochastic Oscillator | 1.69 | 11.09 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.